On March 31, 2024, Biora Therapeutics, Inc., a Delaware corporation, filed an amendment to Schedule 13D with the United States Securities and Exchange Commission (SEC), indicating significant investment activity by various entities collectively referred to as the Reporting Persons. The Reporting Persons, primarily investment partnerships and funds managed by Athyrium Capital Management, LP, disclosed shared voting and dispositive power over a substantial number of Biora Therapeutics' common stock shares, amounting to approximately 49.9% of the company's outstanding shares. The detailed filing outlines a series of complex transactions involving preferred stock purchase agreements, convertible promissory notes, and warrants, which have occurred since 2017. These transactions include the conversion of preferred stock and notes into common stock, purchases of common stock and convertible notes, and amendments...Show More

On March 31, 2024, Biora Therapeutics, Inc., a Delaware corporation, filed an amendment to Schedule 13D with the United States Securities and Exchange Commission (SEC), indicating significant investment activity by various entities collectively referred to as the Reporting Persons. The Reporting Persons, primarily investment partnerships and funds managed by Athyrium Capital Management, LP, disclosed shared voting and dispositive power over a substantial number of Biora Therapeutics' common stock shares, amounting to approximately 49.9% of the company's outstanding shares. The detailed filing outlines a series of complex transactions involving preferred stock purchase agreements, convertible promissory notes, and warrants, which have occurred since 2017. These transactions include the conversion of preferred stock and notes into common stock, purchases of common stock and convertible notes, and amendments to warrants and agreements. The Reporting Persons have engaged in various agreements with Biora Therapeutics, including Investors' Rights Agreements, Registration Rights Agreements, and Lock-Up Agreements, which grant them certain rights regarding the registration and sale of securities, as well as voting agreements related to company offerings. The Reporting Persons' activities are described as being for investment purposes, and they may continue to review their investment in Biora Therapeutics and engage in discussions with management and other stakeholders regarding the company's business and strategic direction.